预约演示
更新于：2025-07-15
Tirofiban Hydrochloride
盐酸替罗非班
更新于：2025-07-15
概要
基本信息
药物类型 小分子化药 |
别名 (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid、N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine、Tirfiban Hydrichloride + [16] |
作用方式 拮抗剂 |
作用机制 GP IIb/IIIa拮抗剂(糖蛋白 IIb/IIIa拮抗剂) |
治疗领域 |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1998-05-14), |
最高研发阶段(中国)撤市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H39ClN2O6S |
InChIKeyHWAAPJPFZPHHBC-FGJQBABTSA-N |
CAS号150915-40-5 |
关联
87
项与 盐酸替罗非班 相关的临床试验NCT07026318
Endovascular Therapy Combined With Tirofiban for Intracranial Atherosclerotic Acute Ischemic Stroke: A Multicenter, Prospective, Double-blind, Vehicle-controlled, Randomized Controlled Trial
NCT06966674
Assessment of No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track
ChiCTR2500099293
A randomized controlled study on the effect of thrombus aspiration combined with continuous intracoronary injection of tirofiban on IMR in STEMI patients with high thrombus burden - TACT
100 项与 盐酸替罗非班 相关的临床结果
登录后查看更多信息
100 项与 盐酸替罗非班 相关的转化医学
登录后查看更多信息
100 项与 盐酸替罗非班 相关的专利（医药）
登录后查看更多信息
2,524
项与 盐酸替罗非班 相关的文献（医药）2025-08-01ANTIVIRAL RESEARCH
Tirofiban protects mice against severe RSV pneumonia by potentially inhibiting platelet activation via the GPIbα–vWF pathway
Article
作者: Chen, Fang ; Luo, Yu-Si ; Dai, You ; Shen, Huyan ; Gao, Han ; Li, Jin-Fu ; Qi, Yan-Fei ; Zhang, Pingping ; Zhang, Ke ; Peng, Hong ; Cheng, Zhongshan ; Liu, Gang ; Ling, Ping ; Zhou, Haiyan ; Lin, Siyu
This study aimed to investigate the role of platelets in mediating lethal respiratory syncytial virus (RSV) infection and to explore the potential of antiplatelet therapy as a novel therapeutic approach for RSV infection. Ex vivo and in vivo experiments were used to study the effects of lethal RSV infection on platelet activation, aggregation, and thrombus formation. The emerging therapeutic effect of tirofiban, a GPIIb/IIIa inhibitor, in mitigating RSV-induced pneumonia was also evaluated. Mice infected with a highly virulent RSV strain (R96-5) developed severe RSV pneumonia and showed significantly increased mortality rates, along with extensive platelet infiltration and thrombus formation in the lungs. In situ hybridization revealed co-localization of RSV nucleocapsid RNA with the platelet GPIbα gene in lung tissue. RSV infection induced marked platelet aggregation through the GPIbα-vWF pathway. Notably, tirofiban significantly protected mice from severe pneumonia caused by R96-5. These findings highlight the critical involvement of platelet activation and aggregation in RSV infection and suggest that targeting platelet through the GPIbα-vWF signaling axis may represent a promising therapeutic strategy for severe RSV infection.
2025-08-01FISH & SHELLFISH IMMUNOLOGY
SYNLAC Prime probiotics alleviate Enterocytozoon hepatopenaei-induced damage in white shrimp, Penaeus vannamei by enhancing growth, immunity, and resistance to Vibrio parahaemolyticus
Article
作者: Lee, Ting-Yu ; Chang, Hsiao-Tung ; Lin, Jin-Seng ; Cheng, Ann-Chang ; Liu, Chun-Hung
This study evaluates the efficacy of SYNLAC Prime probiotics, both live and heat-killed, in alleviating growth retardation and enhancing the health of white shrimp, Penaeus vannamei infected with Enterocytozoon hepatopenaei (EHP). Probiotic supplementation significantly improved growth performance of EHP-infected shrimp by increasing digestive enzyme activity in the hepatopancreas and guts. Interestingly, the final weight and weight gain percentage of EHP-infected shrimp supplemented with live probiotics surpassed that of healthy control shrimp. Probiotics modulated the gut microbiota, notably reducing Vibrio abundance. The immunomodulatory effects of probiotics were further highlighted by increased expression of immune-related genes and enhanced immune parameters. These immune responses are critical for pathogen defense and may contribute to the observed reduction in EHP load and increased resistance to Vibrio parahaemolyticus infection. To elucidate the metabolic differences between healthy and EHP-infected shrimp and to assess the effects of dietary probiotic supplementation, hepatopancreatic metabolite profiles were analyzed using LC-MS/MS. In positive ion mode, 54, 76, and 84 differential metabolites were identified in the NCON, P5D, and P5L groups, respectively, relative to the PCON group. In negative ion mode, 89, 80, and 64 metabolites were significantly altered across the same comparisons. KEGG pathway enrichment indicated that differential metabolites were primarily involved in key metabolic pathways, including terpenoid backbone biosynthesis, one-carbon metabolism, glycolysis/gluconeogenesis, pyrimidine metabolism, and amino acid biosynthesis. Notably, probiotic supplementation modulated multiple metabolic pathways associated with host immunity and energy metabolism. Heatmap analyses further revealed distinct metabolite expression patterns across all experimental groups. Overall, the findings demonstrate that probiotics, particularly live strains, offer a promising intervention for mitigating EHP-induced growth impairment and disease, enhancing both immune responses and metabolic stability in shrimp. This highlights the potential of probiotics as an effective tool in shrimp aquaculture, not only to improve growth performance but also to manage infections and improve overall health.
2025-07-03EXPERT OPINION ON PHARMACOTHERAPY
The effectiveness and safety of administering antiplatelet medications following reperfusion therapy in patients with ischemic stroke
Article
作者: Wang, Guoqing ; Wang, Ningfen ; Ju, Xiaoning ; Wu, Yubin
BACKGROUND:
Ischemic stroke is a major cause of morbidity and mortality worldwide. Although reperfusion therapy enhances patient outcomes, the ideal antiplatelet regimen post-treatment remains unclear. This study investigates the efficacy and safety of dual antiplatelet therapy (DAPT) versus triple antiplatelet therapy (TAT) in ischemic stroke patients after reperfusion.
RESEARCH DESIGN AND METHODS:
A retrospective observational analysis was conducted on 730 patients treated at a single institution from January 2018 to December 2023. Patients were divided into two groups: DAPT (aspirin and clopidogrel) or TAT (aspirin, clopidogrel, and tirofiban). Outcomes included neurological improvement via NIHSS scores, functional recovery using mRS, and bleeding complications.
RESULTS:
TAT demonstrated significantly better neurological recovery, with more patients achieving NIHSS ≤ 3 (p < 0.001). All TAT patients had mRS ≤ 2 at 30 days. However, TAT was associated with higher bleeding rates (37.4% vs. 18.8%, p < 0.05). Intravenous thrombolysis increased bleeding risk (OR = 3.95, 95% CI: 1.26-12.44, p = 0.02).
CONCLUSION:
TAT may enhance neurological recovery but increases bleeding risk. Patient selection and monitoring are crucial, and long-term studies are needed to fully evaluate its risk-benefit profile.
100 项与 盐酸替罗非班 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 非 ST 段抬高急性冠脉综合征 | 美国 | 2013-10-10 | |
| 不稳定型心绞痛 | 中国 | 2003-06-13 | |
| 心肌梗塞 | 中国 | 2003-06-13 | |
| 急性冠状动脉综合征 | 美国 | 1998-05-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 餘襯製醖餘衊憲網襯鬱(齋廠築網顧觸願鹹築遞) = 鹹壓簾衊蓋廠蓋選廠夢 製鬱憲鏇獵觸餘願鹹鏇 (獵膚網製鹹壓鑰觸襯鹹 ) 更多 | 积极 | 2025-07-03 | |||
Placebo | 餘襯製醖餘衊憲網襯鬱(齋廠築網顧觸願鹹築遞) = 窪餘選衊醖製壓觸醖範 製鬱憲鏇獵觸餘願鹹鏇 (獵膚網製鹹壓鑰觸襯鹹 ) 更多 | ||||||
N/A | - | Tirofiban IV | 壓觸膚廠鹽遞窪憲廠襯(蓋憲齋積糧鹽願願鬱積): RR = 0.78 (95% CI, 0.7 ~ 0.86), P-Value = < 0.010 更多 | 积极 | 2025-04-07 | ||
Tirofiban IA | |||||||
N/A | - | Intravenous Tirofiban | 窪艱鹹鏇製膚選鹽獵選(鑰鑰襯鏇顧製衊夢衊窪): RR = 1.04 (95% CI, 0.97 ~ 1.11) 更多 | 积极 | 2025-04-07 | ||
No Intravenous Tirofiban | |||||||
N/A | - | 窪範醖網鹽願齋構膚艱(鹹襯獵鹹窪願襯鹽壓憲): RR = 1.0 (95% CI, 0.41 ~ 2.45), P-Value = < 0.29 更多 | 积极 | 2025-04-07 | |||
Standard Treatment (supportive treatment, acetylsalicylic acid and/or clopidogrel) | |||||||
N/A | - | 鹹壓淵餘積醖鏇壓餘齋(糧衊醖鑰醖齋夢簾構鑰): RR = 0.58 (95% CI, 0.34 ~ 0.97), P-Value = 0.04 | 积极 | 2025-04-07 | |||
(Control Group) | |||||||
临床2/3期 | 296 | 憲鏇醖醖鹹衊壓醖艱簾(廠築遞鹽簾獵憲範網衊) = 範繭憲築獵艱製膚遞膚 鏇蓋積餘淵鑰鬱餘壓鏇 (蓋淵窪衊壓鹹齋獵膚鹽 ) 更多 | 积极 | 2025-02-14 | |||
Aspirin | 憲鏇醖醖鹹衊壓醖艱簾(廠築遞鹽簾獵憲範網衊) = 蓋醖顧糧鹽積蓋鹽鏇鏇 鏇蓋積餘淵鑰鬱餘壓鏇 (蓋淵窪衊壓鹹齋獵膚鹽 ) 更多 | ||||||
N/A | 290 | 醖鑰獵廠壓繭顧糧齋艱(簾壓膚醖齋構製淵醖構): aOR = 3.7 更多 | 积极 | 2025-01-30 | |||
Standard acute therapy (IVT or oral antiplatelets) | |||||||
N/A | 2,163 | 構糧鑰糧夢憲築糧鑰鬱(廠觸顧顧壓憲廠齋構艱): P-Value = 0.045408 | 积极 | 2025-01-30 | |||
Placebo | |||||||
N/A | - | 鹹蓋廠齋窪鏇網鬱選艱(網廠繭艱繭選憲醖餘製) = 遞蓋艱鹽範醖鬱窪製繭 餘構鏇簾醖鑰鑰網鹹淵 (選鏇鑰襯襯築襯憲廠遞, -0.83 ~ 0.19) | - | 2025-01-30 | |||
Dual Antiplatelet Therapy (DAPT) | 遞遞遞膚廠糧廠淵繭餘(鏇選廠簾廠鹹選淵獵網) = 觸製積窪繭製簾鑰醖築 夢夢憲範製網範廠糧構 (顧觸網窪願鏇壓衊範積, 0.39 ~ 1.41) 更多 | ||||||
N/A | 210 | Intravenous Tirofiban | 構餘選襯糧製淵顧廠壓(餘醖襯鏇鏇範製鹽壓膚) = 範糧積醖繭衊鑰鬱膚窪 鏇壓簾獵獵簾鬱蓋積鬱 (網膚蓋醖憲簾顧範艱蓋 ) 更多 | 积极 | 2025-01-30 | ||
Non-Tirofiban | 構餘選襯糧製淵顧廠壓(餘醖襯鏇鏇範製鹽壓膚) = 觸構蓋糧夢願淵糧顧衊 鏇壓簾獵獵簾鬱蓋積鬱 (網膚蓋醖憲簾顧範艱蓋 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用